Online citations, reference lists, and bibliographies.
← Back to Search

CD28-mediated Signalling Co-stimulates Murine T Cells And Prevents Induction Of Anergy In T-cell Clones

F. Harding, J. Mcarthur, J. Gross, D. Raulet, J. Allison
Published 1992 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OCCUPANCY of the T-cell antigen receptor is insufficient to induce T-cell activation optimally; a second co-stimulatory signal is required1. Exposure of T-cell clones to complexes of antigen with major histocompatibility complex molecules in the absence of the co-stimulatory signal induces a state of clonal anergy. This requirement for two stimuli for T-cell activation could have an important role in vivo in establishing peripheral tolerance to antigens not encountered in the thymus1,2. The receptor on T cells required for the co-stimulatory stimulus involved in the prevention of anergy has not been identified. The human T-cell antigen CD28 provides a signal that can synergize with T-cell antigen receptor stimulation in activating T cells to proliferate and secrete lymphokines3–6. Here we report that a monoclonal antibody against the murine homologue of CD28 (ref. 7; J.A.G. et al., manuscript in preparation) can provide a co-stimulatory signal to naive CD4+ T cells and to T-cell clones. Moreover, we demonstrate that this co-stimulatory signal can block the induction of anergy in T-cell clones.
This paper references
10.1084/JEM.159.3.716
T cell-activating properties of an anti-Thy-1 monoclonal antibody. Possible analogy to OKT3/Leu-4
K. Gunter (1984)
A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes.
P. Martin (1986)
Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells.
A. Weiss (1986)
10.1038/326505A0
Thy-1-mediated T-cell activation requires co-expression of CD3/Ti complex
K. Gunter (1987)
10.1128/MCB.7.12.4472
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.
C. June (1987)
10.1084/JEM.165.2.302
Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo
M. Jenkins (1987)
Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells.
M. Jenkins (1988)
10.1146/ANNUREV.IY.07.040189.002305
Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.
D. Mueller (1989)
10.1126/SCIENCE.2113314
A cell culture model for T lymphocyte clonal anergy.
R. Schwartz (1990)
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression.
J. Gross (1990)
10.1073/PNAS.87.13.5031
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
P. Linsley (1990)
10.1084/JEM.173.3.721
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
P. Linsley (1991)
10.1084/JEM.174.3.625
Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7
G. Freeman (1991)
CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells.
M. Jenkins (1991)
10.1126/SCIENCE.1900952
Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production.
G. Otten (1991)
10.1073/PNAS.88.15.6575
B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.
C. D. Gimmi (1991)



This paper is referenced by
10.20517/2394-4722.2021.39
CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions
J. E. Haydu (2021)
10.3389/fimmu.2021.673061
Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction
Rémi Bunet (2021)
10.1053/j.gastro.2021.04.036
Tumor secreted extracellular vesicles regulate T-cell costimulation and can be manipulated to induce tumor specific T-cell responses.
Xianda Zhao (2021)
10.1155/2021/5300381
Immune Checkpoints: Therapeutic Targets for Pituitary Tumors
Ding Nie (2021)
10.3390/cancers13030549
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
J. Heitmann (2021)
10.1042/CS20201236
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.
J. van den Bulk (2021)
10.1002/ANBR.202100021
An Engineered Prussian Blue Nanoparticles-based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH-MYCN Neuroblastoma Model.
Anshi Shukla (2021)
James P. Allison-Nobel Lecture: Immune Checkpoint Blockade in Cancer Therapy
J. Allison (2021)
10.1016/j.transproceed.2021.04.003
VAV1 Gene Polymorphism is Associated With Kidney Allograft Rejection.
M. Wiśniewska (2021)
10.3390/ijms22063228
Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma
A. Chacon (2021)
10.1016/j.esmoop.2020.100011
How we treat endocrine complications of immune checkpoint inhibitors.
S. Paschou (2021)
10.1016/J.AQUACULTURE.2021.737160
Identification and characterization of CD152 in Nile tilapia (Oreochromis niloticus) playing roles in host immune response against bacterial pathogens
Siwei Wu (2021)
10.1038/s41577-021-00541-y
Metabolic barriers to cancer immunotherapy.
Kristin Depeaux (2021)
10.37349/ETAT.2021.00039
Gastrointestinal disorders as immune-related adverse events
Daniele Balducci (2021)
10.1007/s10620-021-06968-6
Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis
A. Czaja (2021)
10.1186/s13046-021-02068-5
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy
Baokang Wu (2021)
10.1002/kjm2.12375
Mechanisms of immunogenic cell death and immune checkpoint blockade therapy
Richard A Lin (2021)
10.1186/s12974-019-1677-z
Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis
Lisa Thiele née Schrewe (2020)
10.20900/immunometab20200020
T Cell Metabolism in Cancer Immunotherapy
H. Aksoylar (2020)
10.1177/1758835920962963
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Qing Cai (2020)
10.3389/fimmu.2020.621623
An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer
Hongfei Yan (2020)
10.3390/ijerph17093214
VAV1 Gene Polymorphisms in Patients with Rheumatoid Arthritis
A. Pawlik (2020)
10.1101/2020.04.29.068841
Human milk extracellular vesicles target nodes in interconnected signalling pathways that enhance oral epithelial barrier function and dampen immune responses
Marijke I. Zonneveld (2020)
10.3390/membranes10120443
Regulations of T Cell Activation by Membrane and Cytoskeleton
Y. Kaizuka (2020)
10.18231/j.jooo.2020.008
Immunotherapy in head and neck cancer: A review
S. Bhateja (2020)
10.3390/biom10071061
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Alexandre Perrier (2020)
10.3390/cells9112470
The Multifaceted Output of c-Jun Biological Activity: Focus at the Junction of CD8 T Cell Activation and Exhaustion
A. Papavassiliou (2020)
10.1101/2020.04.22.055632
Tumor secreted extracellular vesicles regulate T-cell costimulation and can be manipulated to induce tumor specific T-cell responses
Xianda Zhao (2020)
10.1016/j.cellimm.2020.104130
Engagement of CD45 alters early signaling events in human T cells co-stimulated through TCR + CD28.
Anuja Bhatta (2020)
10.1016/j.immuni.2019.12.018
Tumor Immunology and Tumor Evolution: Intertwined Histories.
J. Galon (2020)
10.20381/RUOR-25170
Characterization of the Immune Response Induced by Rhabdovirus-Infected Leukemia Cell Vaccines
Elena Scut (2020)
10.1016/j.ecl.2020.05.002
A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Stuti Fernandes (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar